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Abstract
A methodology is proposed, based on Raman spectroscopy coupled with multivariate analysis,
to determine the Limit of Detection (LOD) and Limit of Quantification (LOQ) for therapeutic
drug monitoring in human serum, using the examples of Busulfan, a cell cycle non-specific
alkylating antineoplastic agent, and, Methotrexate, a chemotherapeutic agent and immune
system suppressant. In this study, ultrafiltration is employed to fractionate spiked human
pooled serum to efficiently recover the drug in the filtrate prior to performing Raman analysis.
The drug concentration ranges were chosen to encompass the recommended therapeutic ranges
and toxic levels in patients. Raman spectra were collected from the filtrates in the liquid form,
using an inverted backscattering microscopic geometry, using 532nm as source. Finally,
prediction models were built by using Partial Least Squares Regression (PLSR) and LOD and
LOQ were calculated directly from the linear prediction models. The LOD calculated for
Busulfan is 0.0002 ± 0.0001 mg/mL, 30-40 times lower than the level of toxicity, enabling the
application of this method in target dose adjustment of Busulfan for patients undergoing, for
example, bone marrow transplantation. The LOD and LOQ calculated for Methotrexate are 7.8
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± 5 µM and 26 ±5 µM, respectively, potentially enabling high dose monitoring. The promising
results obtained from this study suggest the potential of Raman spectroscopy for therapeutic
drug monitoring of drugs in bodily fluids.
Keywords:
Raman spectroscopy, Therapeutic Drug Monitoring, Busulfan, Methotrexate, Limit of
detection, Limit of quantification, Partial least squares regression analysis
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Introduction
Therapeutic drug monitoring (TDM) refers to the clinical practice of management of a patient's
drug dosage within a targeted therapeutic window, based on measurement of concentration of
the drug in the bloodstream at timed intervals. For drugs with a narrow therapeutic range, such
monitoring is essential to provide individualised patient treatment, while maintaining the
efficacy of drugs and minimising drug toxicity and related adverse effects (1,2).
TDM has also been increasingly advocated to improve the standard of chemotherapy, in which
side effects can be substantial and life threatening (3–6). The currently available technique of
chemotherapeutic-dosage calculation based on dose intensity and body surface area has been
reported to be inaccurate for patients undergoing sustained chemotherapeutic treatment (7,8).
In the era of rising cost of healthcare, it is necessary to develop a rapid, sensitive, and costeffective, point-of-care technique for TDM, which can quantitatively measure the serum
concentration of drugs, such that the dosing strategy can be tailored to the metabolism of an
individual patient for a personalised therapeutic regime.
Busulfan (Bu) is a bi-functional alkylating agent (see chemical structure in inset of Figure 2A)
used in the chemotherapy-based conditioning regimen for hematopoietic stem cell
transplantation (HSCT) (9–17). Bu has a very narrow therapeutic index, and higher systemic
exposure to Bu is related to hepatic sinusoidal obstruction syndrome, neurotoxicity or
insterstitial pneumonia, while low levels have been shown to be associated with increased
incidence of graft rejection (18–21). Measurement of individual serum Bu levels during oral or
intravenous dosing is likely to provide the necessary elements to monitor the drug disposition,
ensuring efficacy, reduced incidences of toxicity and graft rejection (18–22). Several analytical
methods, including chromatographic techniques coupled with a number of detection methods,
have been described for analysing Bu in biological fluids; Gas chromatography (GC) with
electron capture detection, high performance liquid chromatography (HPLC) with UV
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detection, GC-Mass spectroscopy (MS) with selected ion monitoring, and Enzyme linked
immunosorbent assays (ELISA) have been reported to have high sensitivity for monitoring Bu
in biological fluids (10,11,23–26). However, the translation of these techniques to a routine
analytical tool in a clinical setting for TDM is impractical, owing to their complexity and cost.
Methotrexate (MTX) is a folate antagonist (see chemical structure in the inset of Figure 2B)
widely used as an anti-cancer agent to treat various malignancies, such as leukemia, breast
cancer, lymphomas and autoimmune diseases (27). MTX is administered in both low and high
dosage (LDMTX and HDMTX), and monitoring serum MTX concentrations is essential to
avoid high dosage related side effects (28). Serum MTX concentrations can vary from 10 nM
to 1 mM for different patients, due to pharmacokinetic variability (28). The serum MTX
concentration should reach between 10µM (0.001mM) and 100µM (0.01mM) after 12-36 hours
of HDMTX infusion and should reduce to 0.2µM after 72 hours. From the clinical point of
view, it is essential to be able to detect the serum concentrations of MTX between 0.1µM and
10µM, as high toxicity related adverse effects are associated with concentrations >10µM
(28,29). Various sophisticated analytical tools such as Enzyme multiplied immunoassay
technique (30), radioimmunoassay (31), enzyme exhibition assays (32), capillary zone
electrophoresis (33) and liquid chromatography coupled with tandem mass chromatography
(HPLC-MS/MS)(6,34–39) have been reported for TDM of MTX from biological fluids.
Although immunoassays (40) and separation techniques (38) are routinely employed due to,
they suffer from major limitations such as interferences from other compounds and lack of
availability for all the drugs currently monitored (4). HPLC-MS/MS is considered the gold
standard method for MTX (35-39) analysis due to its high sensitivity and robustness; however,
it is time consuming, expensive and requires skilled personnel.
In recent years, Surface enhanced Raman spectroscopy (SERS) has been reported to be a good
candidate for TDM of MTX (28,29,41), doxorubicin (42), paclitaxel and cyclophosphamide
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(3) in biological fluids, since quantitative analysis of drugs can be performed rapidly and higher
sensitivity. By comparison, quantification of Bu in biological fluids using spectroscopic
techniques has not been explored. Critical issues of using SERS for TDM include development
of standardised substrates, intense surface enhanced resonance SERS responses from other
biological molecules such as carotenoids and also the spectral interference from the
fluorescence that could interfere with the drug detection (28,43). Therefore, new techniques
that are inexpensive, less complex and faster are essential to quantitatively determine the
concentration of drugs in a clinical setting. Herein, a rapid drug screening strategy using Raman
spectroscopy coupled with ultrafiltration and multivariate analysis technique for Bu and MTX
from liquid serum that yields a significant improvement in detection capabilities and minimises
error is explored.

Materials and Methods
Materials
Methotrexate (A6770), Busulfan (B058) and human pooled serum (H6194) were purchased
from Sigma Aldrich, Ireland. Stock solutions of 0.1mg/mL Bu in methanol and 1mM MTX in
0.1M NaOH were prepared. The spiked concentrations of Bu in serum are expressed in mg/mL
and MTX in µM to be consistent with previous studies (4,29). The commercial human serum
was spiked with Bu and MTX over the therapeutically relevant concentration ranges, to achieve
the final concentrations of (0 - 0.05 mg/mL) for Bu and (0 – 100 µM) for MTX. The normal
therapeutic range for Bu is 0.0005mg/mL to 0.005mg/mL and any concentration below
0.0005mg/mL can cause transplant failure, or higher than 0.005mg/mL, transplant related
mortality (11), whereas for MTX, 1µM to 10µM and <10µM is considered toxic (29). Raman
spectra of highly concentrated Bu and MTX drug solutions prepared with a minimal amount
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of water (~1mg/mL) are used as the reference for the Extended Multiplicative Signal
Correction algorithm (see Data pre-processing and analysis ).
Amicon Ultra 0.5mL centrifugal filter devices (Millipore- Merck, Germany), with a cut off
point of 10kDa, were employed to fractionate the serum samples. The centrifugation procedure
previously reported by Bonnier et al. was followed (44). The optimised washing and rinsing
procedure includes spinning 0.5mL 0.1M NaOH at 14000×g for 30 minutes, followed by three
rinses with distilled water by spinning 0.5mL distilled water for 30 minutes at 14000×g. Every
30 minute wash and rinse must be followed by spinning the device in the inverted position at
1000×g for 2 minutes, to remove the residual solution contained in the filter. After washing,
0.5mL of spiked serum solution is transferred to the 10kDa filter and centrifuged at 14000×g
for 30 minutes. The filtrate that passes through the 10kDa filter contains mostly water and
molecules smaller than 10kDa. All the filtrate solutions were analysed using Raman
spectroscopy and five replicate measurements from different positions have been recorded. In
subsequent analysis, each dosed serum sample is represented by all the spectra recorded from
that sample, rather than the mean.

Raman spectroscopy
The measurement conditions used for screening analytes in human serum in the liquid form
have recently been detailed (45,46). Raman spectra of all the liquid serum filtrate samples and
references were recorded at stabilised room temperature (18ºC) using a Horiba Jobin-Yvon
LabRam HR800 spectrometer with a 16-bit dynamic range Peltier cooled CCD detector. A
532nm laser was used, which had a power of ~30 mW at the sample, with a 600 lines/mm
grating and the backscattered Raman signal was integrated for 3×80 seconds over the spectral
range from 400-1800 cm-1. The spectrometer was coupled to an Olympus 1X71 inverted
microscope and a x60 water immersion objective (LUMPlanF1, Olympus) was employed. The
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substrate used was a Lab-Tek plate (154534) with a 0.16-0.19mm thick, 1.0 borosilicate glass
bottom, and was purchased from Thermo Fischer Scientific, Ireland.

Data pre-processing and analysis
The raw spectra were subjected to pre-processing techniques in Matlab before further analysis,
to remove the background signal and reduce the noise. Smoothing of the raw data was done
using the Savitzky–Golay method (polynomial order of 5 and window 13) and the rubberband
method (45) was found to be appropriate to baseline correct the smoothed reference spectra of
both the drugs. The ‘rubberband’ correction was carried out by wrapping a ‘rubberband’ of
defined length around the ends of the spectrum to be corrected and fitting against the curved
profile of the spectrum. An adapted Extended Multiplicative Signal Correction (EMSC)
algorithm (47), with a 3rd order polynomial, was applied to remove the underlying water
spectrum from all the dataset, whose OH bending feature at 1640 cm-1 can interfere with the
analyte spectra, and also scales the analyte spectra, assuming a constant water contribution to
all sample spectra (47).

Partial Least Squares Regression
Partial Least Squares Regression (PLSR) was employed to establish a model that relates the
variations of the spectral data to a series of concentrations. This regression model can be used
to establish the limit of detection and quantitation of Raman bio-sensing of drugs (48,49).
Constructed based on the spectra of samples of known drug content, over a range of varying
concentrations of drug (in commercial serum), the model is then validated using a rigorous
cross validation procedure which evaluates its performance in accurately predicting drug
concentrations. For consistency with previous studies (45,46), a 20 fold cross validation
approach has been employed to validate the robustness of the method. This approach involves
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randomly dividing the set of observations into approximately equal size, 50% of the spectral
data were randomly selected as test set, while the remaining 50% is used as the training set
(50). The cross-validation process is then repeated 20 times (the folds), whereby all
observations are used for both training and testing, and each observation is used for testing
exactly once. The results from the folds can then be averaged to produce a single estimation.
The Root Mean Square Error of Cross Validation (RMSECV) is calculated from the 20
iterations to measure the performance of the model for the unknown cases within the calibration
set. The correlation between the true and predicted concentrations is given by the R2 value. The
standard deviation was calculated to quantify the amount of variation in the dataset. The
number of latent variables used for building the PLSR model is optimised by finding the value
that is equivalent to the minimum of the RMSECV. The Limit of Detection (LOD) and Limit
of Quantification (LOQ) of these two drugs for this method were calculated from the PLSR
prediction plot, using a IUPAC-consistent approach previously reported for multivariate
regression analysis by Ostra et al. (48).
LOD = 3 x Sblank x b

(1)

LOQ = 10 x Sblank x b (2)
where, Sblank is the standard deviation of a blank (zero concentration sample) and b is the slope
of the regression (inverse calibration) model, in the region of linearity. The slope was
calculated for the linear region of the prediction plot, including the standard deviation of each
point, by initially regressing over the higher concentrations, and progressively adding smaller
concentrations to the regression range, until the calculated slopes were seen to begin to reduce.

Results and Discussion
Figure 1 shows the schematic diagram of the strategy used to collect the Bu and MTX data
from the serum samples to build the prediction models.
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Figure 1. Schematic representation of the ultra-centrifugation, Raman analysis, data preprocessing and PLSR analysis of the Bu/MTX serum samples
The advantages of employing an inverted geometry to record Raman spectra have been detailed
by Bonnier et al (51). The feasibility of using a Lab-Tek plate as substrate (45) and impact of
ultra-filtration coupled with multivariate analysis techniques in detecting low molecular weight
fraction analytes have also previously been reported (46,52,53). The Raman spectra recorded
from the 10kDa filtrate of Bu and MTX spiked serum samples were subjected to pre-processing
steps followed by PLSR analysis. The whole finger print region (400-1800cm-1) was chosen to
build PLSR prediction for Bu, whereas a shorter region, in which there are strong bands of
MTX (1200-1800cm-1), was chosen to facilitate efficient prediction of MTX by increasing the
sensitivity. The improvement of the sensitivity of the prediction model for the case of glucose
and urea when regressed over a reduced spectral region was previously reported (46,54). The
normal and toxic ranges of the Bu and MTX were encompassed by the range of spiked serum
samples.
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Figure 2.A: Reference spectrum of Bu used for EMSC correction. The chemical structure of
Bu is shown in the inset. B: Reference spectrum of MTX used for EMSC correction. The
chemical structure of MTX is shown in the inset. C: PLSR coefficient plot of Bu (400-1800cm1
) from serum filtrate concentrations showing spectral features similar to the Bu reference at
1097cm-1 and 1453cm-1. D: PLSR coefficient plot of regression against MTX from 12001800cm-1 showing spectral features similar to the MTX reference at 1351cm-1, and 1593cm-1.
RMSECV were calculated to be 0.0003mg/mL for Bu and 4.02 µM for MTX, respectively
Figure 2A shows the reference spectrum of Bu, and the signature peaks of Bu at 1097cm-1 and
1453cm-1, which can be ascribed to a CH2 scissoring mode and C-C stretching, respectively
(55). In the case of MTX, the signature peaks are a strong band at 1593cm-1, which can be
ascribed to the scissoring of the NH2 group, while the sharp band at 1351cm-1 can be ascribed
to CH2 scissoring vibrations (Figure 2B) (4,29,41). The pre-processed data set of systematically
varied concentration of spiked, filtered serum (Figure S1A and B) is fed into the PLSR
algorithm to build a prediction model that correlates the known concentration and the predicted
concentration, based on the variation in spectral intensity, for each drug. On the basis of the
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percent variance explained by the latent variables and the lowest value of RMSECV, the total
number of latent variables used to reach the best performance is calculated to be 3 for both Bu
and MTX (Figure S3A and B). The RMSECV values are calculated to be 0.0003mg/mL for Bu
and 4.02µM for MTX. The PLSR coefficient plots (Figure 2C and D) of Bu and MTX display
Raman bands in good accordance with the reference ones, namely, the presence of peaks at
1097cm-1 and 1453cm-1 for Bu, and 1593cm-1, and 1351cm-1 for MTX, respectively.

Y=0.96*x-2.5e-06

A

Y=0.94*x +1.4

B

B

Figure 3: Linear predictive model for (A) Bu and (B) MTX built from the PLSR analysis. The
LOD and LOQ for Bu were calculated to be 0.0002±0.0001mg/mL and
0.00073±0.00010mg/mL, whereas the LOD and LOQ of MTX were calculated to be 7.8 ±5.0
µM and 26 ±5µM.
Figure 3A and B indicate that the concentration dependence of the sample set is conserved by
centrifugal filtration and a satisfactory linear model could be obtained for Bu and MTX from
the filtrate of the serum samples. A linear prediction plot with a correlation accuracy (R2) of
0.97 was obtained for Bu, with an LOD of 0.0002 ±0.0001mg/mL and LOQ of 0.00073
±0.0001mg/mL (b=0.96 and Sblank= 0.00008mg/mL), both in the acceptable range of clinical
use. Figure S2A and B show that the signature peaks of Bu and MTX are discernible at the
detection of limits identified by the respective PLSR models. Samples with Bu concentrations
higher than 0.002mg/mL are frequently observed in many hospitals, but, Bu concentrations
less than 0.0005mg/mL are rarely seen (11). This Raman spectral response was validated to be
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linear over the entire range of 0.0003mg/mL to 0.0125mg/mL, which has not been fully
validated in previous studies. In comparison to the earlier studies based on LC-MS, the present
method shows similar performances in precision and recovery (13,16,24,56). However,
considering the time needed for sample preparation for the chromatography based methods, the
present method has an added advantage that it does not require complex sample preparation
steps. Besides, the amount of sample required for this method (1-50 μL) is slightly less than
that for other commonly employed methods (50 to 200 μL)(11). Thus, this proposed approach
can be expeditiously implemented in laboratories in clinical settings for introduction of TDM
of Bu to achieve safe and proper dosing.
Similarly, the correlation accuracy (R2) is as high as 0.96 for MTX. The LOD was calculated
to be 7.8 ±5.0µM and the LOQ to be 26 ±5 µM (b=0.94 and Sblank = 2.8 µM). High risk of
toxicity related adverse effects are associated with serum MTX concentrations of >10µM
(4,29). The concentrations outside of safety values of MTX are >10 µM at 24 hours or >1 µM
at 48 hours, and the serum MTX concentration should drop down to 0.2µM after 72 hours to
reach the safety value (4,29,57,58). For most drugs, the process of drug elimination is a firstorder rate process, and so, in a given patient, can be characterised by a rate constant (59).
Therefore, from the clinical point of view, regular monitoring of MTX levels in patient serum
can be used to determine a rate of drug elimination and help establish a personalised dosing
regime for each patient. In previous studies, many researchers have reported the use of SERS
substrates to detect MTX in plasma/serum with a LOD as low as 0.17μM (29). Although SERS
gives promising results in detecting drugs at low concentrations in biological matrices (28, 29),
qualitative variations within the SERS substrate (60), the interference of other biomolecules
with the SERS spectra, makes quantification in real samples a challenging task (43).
Alternatively, Bonifacio et al. demonstrated the use of Ag and Au colloids as SERS substrates
to obtain intense and repeatable spectra from serum filtrate (61).

12

In contrast, the proposed method with inverted Raman spectroscopy is cost-effective and easy
to use, that can be translated as a point-of-care diagnostic tool for high-dosage MTX in bodily
fluids. Notably, in determining the LOD and LOQ, while the slope of the concentration
dependent response is dependent on the Raman scattering cross section of the analyte, the
standard deviation of the blank is a measurement parameter, and instrument specific, and could
potentially be improved by reduced noise and/or signal variability.
Conclusion
In summary, a rapid, sensitive, cost effective and reproducible method to determine the Bu and
MTX levels in human serum has been demonstrated. In clinical practice, identification of
individual therapeutic concentration of drugs is crucial for specific drugs with narrow
therapeutic window by measuring the levels of these drugs at designated intervals in the
serum/plasma, as the drug concentration in serum/plasma largely varies with time for different
individuals based on their age, body weight, pregnancies, temporary illnesses, infections,
emotional and physical stresses, accidents, and surgeries (12,58,62–64). TDM takes these
factors into consideration and accommodates them while establishing an individual therapeutic
concentration to fit the specific needs of a patient. This simple approach of Raman spectroscopy
coupled with ultracentrifugation and multivariate analysis technique allows to effectively
preserve the information in the filtrate while enabling easy detection of the drug concentration
with higher accuracy. This strategy could be widely adopted for monitoring a variety of other
drugs and small molecules. The present method accurately determines MTX concentrations at
7.8±5.0µM, suggesting that this method can be applied for high dose monitoring of MTX. On
the other hand, this method determined the concentration of Bu as low as
0.0002±0.0001mg/mL, which is 30-40 fold below the lowest Bu level that may present a risk
for toxicity (19), thus ensuring effective and safe therapy for patients undergoing bone marrow
transplant. Therefore, this can be a useful protocol for TDM of Bu to achieve safe and
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appropriate dosing. Further studies are needed to investigate the determination of these drugs
in patient serum to ensure successful implementation of this method as a diagnostic tool. Thus
far, this study is a proof of concept that simple Raman spectroscopy combined with multivariate
analysis technique and ultrafiltration has the potential to be used as a diagnostic tool for
therapeutic drug monitoring from human serum.
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